^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

TROP2 overexpression

i
Other names: TROP2, Trophoblast Cell Surface Antigen 2, Tumor Associated Calcium Signal Transducer 2, Membrane Component Chromosome 1 Surface Marker 1, Tumor-Associated Calcium Signal Transducer 2, Pancreatic Carcinoma Marker Protein GA733-1, Cell Surface Glycoprotein Trop-2, Epithelial Glycoprotein-1, GA733-1, M1S1, Gastrointestinal Tumor-Associated Antigen GA733, Pancreatic Carcinoma Marker Protein GA7331, Cell Surface Glycoprotein TROP2, Truncated TACSTD2, GA7331, EGP-1, GP50 , TACSTD2
Entrez ID:
Related biomarkers:
1m
Phase 3 MK-2870-007 study: MK-2870 (SKB264) plus pembrolizumab vs pembrolizumab alone as first-line treatment for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50% (AACR 2024)
AEs will be graded according to National Cancer Institute Common Terminology Criteria for Adverse Events v5.0. Enrollment began in December 2023 and is currently ongoing.
Clinical • PD(L)-1 Biomarker • IO biomarker • Tumor proportion score • Metastases
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
|
TROP2 expression • TROP2 overexpression
|
PD-L1 IHC 22C3 pharmDx
|
Keytruda (pembrolizumab) • sacituzumab tirumotecan (MK-2870)
2ms
Correlative Assessment of Predictive Biomarkers (FOLR1, HER2, and TROP2) in Endometrial Carcinoma (USCAP 2024)
Our results showed overexpression of FOLR1 and TROP2 in a significant proportion of high-grade EC, suggesting that targeted therapy against these markers may be a novel option for patients with EC. FOLR1 and HER2 positivity appeared mutually exclusive, while co-expression of FOLR1-TROP2 and HER2-TROP2 was also infrequent, observed in <5% of all tumors.
HER-2 (Human epidermal growth factor receptor 2) • FOLR1 ( Folate receptor alpha ) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
|
HER-2 positive • HER-2 overexpression • HER-2 expression • TROP2 expression • TROP2 overexpression • FOLR1 overexpression
|
VENTANA FOLR1 RxDx Assay
2ms
DNA demethylation and tri-methylation of H3K4 at the TACSTD2 promoter are complementary players for TROP2 regulation in colorectal cancer cells. (PubMed, Sci Rep)
Treatment with 5-Azacytidine, a DNMT1 inhibitor, led to demethylation of the TACSTD2 promoter accompanied by an increase in TROP2 protein expression...Our data provide novel evidence for promoter demethylation and simultaneous gains of the active histone mark H3K4me3 across CpG-rich sequences, both being complementary mechanisms in the transcriptional regulation of TACSTD2 in colon cancer. The functional consequences of TROP2 loss in colorectal cancer needs to be further investigated.
Journal • Epigenetic controller
|
TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
|
TROP2 expression • TROP2 overexpression
|
azacitidine
3ms
High expression of Trop2 is associated with aggressive localized prostate cancer and is a candidate urinary biomarker. (PubMed, Sci Rep)
Additionally, we detect shed Trop2 in urine from men with clinically significant prostate cancer. Our study identifies Trop2 as a novel tissue prognostic biomarker and a candidate non-invasive marker for prostate cancer.
Clinical • Journal
|
TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
|
TROP2 expression • TROP2 overexpression
4ms
Expression Analysis of Early Metastatic Seeding of Colorectal Cancer. (PubMed, Ann Surg Oncol)
Gene expression analysis revealed that TROP2, VWCE, and BMP7 were involved in early metastatic seeding. The high expression of these genes may warrant careful surveillance or adjuvant therapy, even in stages I-II CRC cases.
Journal • Metastases
|
TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
|
TROP2 overexpression
5ms
TROP2 is associated with primary resistance to immune checkpoint inhibition in patients with advanced non-small cell lung cancer. (PubMed, Clin Cancer Res)
Our results suggest an important contribution of TROP2 expression to the primary resistance to PD-L1 blockade in NSCLC. TROP2-biomarker-based strategy may be relevant in selecting NSCLC patients who are more likely to benefit from a combination of immunotherapy and an anti-TROP2 agent.
Clinical • Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker • Metastases
|
TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
|
TROP2 expression • TROP2 overexpression
|
Tecentriq (atezolizumab)
5ms
Assessment of PD-L1, TROP2, and nectin-4 expression in penile squamous cell carcinoma. (PubMed, Hum Pathol)
High expression of TROP2 and nectin-4 in pSCC support evaluation of these markers as therapeutic targets pending validation of our findings.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • NECTIN4 (Nectin Cell Adhesion Molecule 4) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
|
PD-L1 expression • PD-L1 negative • TROP2 expression • TROP2 overexpression • NECTIN4 expression
|
PD-L1 IHC 22C3 pharmDx
5ms
hIMB1636-MMAE, a Novel TROP2-Targeting Antibody-Drug Conjugate Exerting Potent Antitumor Efficacy in Pancreatic Cancer. (PubMed, J Med Chem)
It displayed significant tumor-targeting ability and excellent tumor-suppressive effects in vivo, resulting in 5/8 tumor elimination at 12 mg/kg in the T3M4 xenograft model or complete tumor disappearance at 10 mg/kg in BxPc-3 xenografts in nude mice. Its half-life in mice was about 87 h. These data suggested that hIMB1636-MMAE was a promising candidate for the treatment of pancreatic cancer with TROP2 overexpression.
Journal
|
TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
|
TROP2 expression • TROP2 overexpression
|
hIMB1636-MMAE
7ms
ImmunoPET imaging of Trop2 expression in solid tumors with nanobody tracers. (PubMed, Eur J Nucl Med Mol Imaging)
In the work, we reported two nanobody tracers targeting human Trop2 which may facilitate better use of Trop2-targeted therapeutics by noninvasively displaying expression dynamics of the target.
Journal
|
TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
|
TROP2 expression • TROP2 overexpression
8ms
Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan. (PubMed, NPJ Breast Cancer)
In metaplastic breast cancers (MpBC), there is limited expression of TROP2, and downregulating transcription factor ZEB1 upregulates E-cad and TROP2, thus sensitizing cancers to TROP2 ADC sacituzumab govitecan (SG). Decitabine also increases SLFN11, a biomarker of topoisomerase 1 inhibitor (TOP1) sensitivity and is synergistic with SG which has a TOP1 payload, in TROP2-expressing SLFN11-low BC cells. In conclusion, TROP2 and SLFN11 expression can be epigenetically modulated and the combination of demethylating agent decitabine with TROP2 ADCs may represent a novel therapeutic approach for tumors with low TROP2 or SLFN11 expression.
Journal
|
SLFN11 (Schlafen Family Member 11) • ZEB1 (Zinc Finger E-box Binding Homeobox 1) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
|
TROP2 expression • SLFN11 expression • TROP2 overexpression • ZEB1 expression
|
decitabine • Trodelvy (sacituzumab govitecan-hziy)
9ms
Evaluation of Potential Therapeutic Targets with Experimental or FDA-approved Therapies in Thymic Tumor Microarrays (IASLC-WCLC 2023)
Consistent high expression of TROP2 protein in thymoma and thymic carcinoma suggest a potential therapeutic role for anti-TROP2 antibody-drug conjugates in metastatic tumors
FDA event • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • FOLH1 (Folate hydrolase 1) • SLC2A1 (Solute Carrier Family 2 Member 1) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
|
PD-L1 expression • HER-2 expression • TROP2 expression • TROP2 overexpression • FOLH1 expression
10ms
TROP2 translation mediated by dual mA/mG RNA modifications promotes bladder cancer development. (PubMed, Cancer Lett)
Furthermore, TROP2 expression was significantly positively correlated with the expression levels of METTL3 and METTL1 in BCa patients. Overall, our results revealed that METTL3/METTL1-mediated dual mA/mG RNA modifications enhanced TROP2 translation and promoted BCa development, indicating a novel RNA epigenetic mechanism in BCa.
Journal
|
TROP2 (Trophoblast Cell Surface Antigen 2) • METTL1 (Methyltransferase 1, TRNA Methylguanosine) • METTL3 (Methyltransferase Like 3) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
|
TROP2 expression • TROP2 overexpression
12ms
TROP2 expression and response to immune checkpoint inhibition in patients with advanced non-small cell lung cancer. (ASCO 2023)
We analyzed the largest NSCLC gene expression data set worldwide including the whole-transcriptome profile of 891 pre-treatment tumors from POPLAR and OAK trials, two randomized studies assessing the efficacy of atezolizumab versus docetaxel in NSCLC. Our study revealed that TROP2 expression by tumor cells in NSCLC is associated with worse outcome in patients with NSCLC independently of PDL1 expression. Targeting TROP2 in combination with ICI may represent a promising strategy to improve ICI efficacy in pts with TROP2-high NSCLC.
Clinical • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker • Metastases
|
TROP2 (Trophoblast Cell Surface Antigen 2) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
|
PD-L1 expression • TROP2 expression • TROP2 overexpression
|
Tecentriq (atezolizumab) • docetaxel
12ms
Trop-2 mRNA expression and association with clinical outcomes with sacituzumab govitecan (SG) in patients with HR+/HER2– metastatic breast cancer (mBC): Biomarker results from the phase 3 TROPiCS-02 study. (ASCO 2023)
This mRNA-based biomarker analysis demonstrated that SG improves PFS and OS outcomes in patients with pretreated, endocrine-resistant HR+/HER2– mBC regardless of Trop-2 mRNA expression. There was no correlation between Trop-2 mRNA expression and HER2 status. Trop-2 mRNA expression was not predictive of benefit with SG.
Clinical • Clinical data • P3 data • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • TROP2 (Trophoblast Cell Surface Antigen 2) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
|
HER-2 expression • TROP2 expression • TROP2 overexpression
|
Trodelvy (sacituzumab govitecan-hziy)
1year
Antibody-drug conjugates (ADCs) targeting TROP-2 in lung cancer. (PubMed, Expert Opin Biol Ther)
Anti-TROP-2 ADCs represent an innovative upcoming weapon against both non-small cell lung cancer and small cell lung cancer subtypes, pending the results of several ongoing trials. The proper combination and placement of this agent throughout the lung cancer treatment pathway, the identification of potentially predictive biomarkers of benefit, as well as the optimal management and impact of peculiar toxicity (i.e. interstitial lung disease) are the next questions to be answered.
Journal
|
TROP2 (Trophoblast Cell Surface Antigen 2)
|
TROP2 overexpression
|
Trodelvy (sacituzumab govitecan-hziy) • datopotamab deruxtecan (DS-1062a)
1year
Recombinant Immunotoxin exhibited targeted killing of Trop2 overexpressing tumour cells lines (AACR 2023)
Here, we demonstrated antigen specific killing of Trop2 overexpressing tumor cells in vitro. Targeted deployment of recombinant immunotoxin to specifically engage and kill Trop2 positive cells is a potential approach for cancer therapeutics. As such, the ability of the rIT to specifically target and kill Trop2 expressing tumors is an important initial finding towards the possibility of antigen-dependent elimination of Trop2 expressing cancer cells.
Tumor cell
|
CKB (Creatine Kinase B) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
|
TROP2 expression • TROP2 overexpression • TROP2 positive
1year
Discovery of BCG033, a novel anti-PTK7 x TROP2 bispecific antibody-drug conjugate with promising efficacy against triple-negative breast cancer (AACR 2023)
Recently, the TROP2-targeting ADC sacituzumab govitecan has received an accelerated approval from the FDA for adult patients with metastatic TNBC, as more than 85% of TNBC is marked by TROP2 overexpression. Patient-derived TNBC xenografts with co-expression of PTK7 and TROP2 have been screened for future in vivo drug efficacy screening. In summary, BCG033 has the potential to exert anti-tumor efficacy in TNBC and other solid tumors co-expressing PTK7 and TROP2.
Clinical • Late-breaking abstract
|
TROP2 (Trophoblast Cell Surface Antigen 2) • PTK7 (Protein Tyrosine Kinase 7) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
|
TROP2 expression • TROP2 overexpression
|
Trodelvy (sacituzumab govitecan-hziy) • BCG033
1year
Propionate-producing Veillonella parvula regulates the malignant properties of tumor cells of OSCC. (PubMed, Med Oncol)
Culture supernatant of Veillonella parvula NCTC11810 promoted the apoptosis and inhibited the proliferation and invasion ability of HN6 cells, while sodium propionate (SP), the main metabolite of Veillonella parvula NCTC11810, played a similar role through the inhibition of TROP2/PI3K/Akt pathway. Studies above supported the proliferation-inhibiting, invasion-inhibiting, and apoptosis-promoting function of Veillonella parvula NCTC11810 in OSCC cells which provided new insights into oral microbiota and their metabolite as a therapeutic method for OSCC patients with TROP2 high expressing.
Journal • Tumor cell
|
TROP2 (Trophoblast Cell Surface Antigen 2) • ANXA5 (Annexin A5) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
|
TROP2 expression • TROP2 overexpression
1year
Construction of a novel TROP2/CD3 bispecific antibody with potent antitumor activity and reduced induction of Th1 cytokines. (PubMed, Protein Expr Purif)
Given that the excessive production of Th1 cytokines induced by CD3-mediated T-cell overactivation may lead to toxicity in the clinic, we devised a strategy to modify this CD3-induced T cell activation by a two-step reduction in the bispecific antibody binding affinity for CD3 to a level that retained the ability of the bispecific antibody to effectively inhibit tumor growth while greatly reducing the amount of Th1 cytokines secreted by T cells. Thus, we provide insight into the design of T cell engagers that exhibit a promising toxicity profile while retaining inhibitory effects on tumor growth.
Journal
|
TROP2 (Trophoblast Cell Surface Antigen 2) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
|
TROP2 overexpression
over1year
The association between trophoblast cell surface antigen 2 expression and nivolumab monotherapy in patients with advanced gastric cancer. (ASCO-GI 2023)
Higher TROP2 expression related to longer survival in the patients with AGC treated with NIVO monotherapy.
Clinical • PD(L)-1 Biomarker • Metastases
|
TROP2 (Trophoblast Cell Surface Antigen 2) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
|
TROP2 expression • TROP2 overexpression
|
Opdivo (nivolumab)
almost2years
TROP2 as Patient-Tailoring but Not Prognostic Biomarker for Breast Cancer. (PubMed, Onco Targets Ther)
The levels of TROP2 expression were determined to be significantly correlated with the potencies of DS001 treatment, but not with the overall survival rates of the patients. Our results demonstrated that TROP2 could serve as a patient-tailoring and predictive biomarker for ADC therapeutics but not as a general prognostic biomarker to predicate patient survival.
Journal
|
TROP2 (Trophoblast Cell Surface Antigen 2)
|
TROP2 expression • TROP2 overexpression
2years
TROP2 Down-Regulated DSG2 to Promote Gastric Cancer Cell Invasion and Migration by EGFR/AKT and DSG2/PG/β-Catenin Pathways. (PubMed, Curr Cancer Drug Targets)
TROP2 promotes gastric cancer cell invasion and migration by decreasing DSG2 expression through EGFR/AKT and DSG2/PG/β-catenin pathways.
Journal
|
EGFR (Epidermal growth factor receptor) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • TROP2 (Trophoblast Cell Surface Antigen 2)
|
EGFR expression • TROP2 expression • TROP2 overexpression
2years
Epigenetically upregulating TROP2 enhances therapeutic efficacy of TROP2 ADC sacitizumab govitecan (AACR 2022)
Sacituzumab govitecan (SG), a humanized anti-TROP2 antibody conjugated with SN-38, was approved for treatment of metastatic triple negative breast cancer, with the greatest efficacy in patients with medium or high TROP2 levels. TROP2 is expressed in most breast cancers, but is expressed less frequently in MpBC, an aggressive subtype unresponsive to traditional therapies. Epigenetic modulator decitabine upregulates TROP2 and SLFN11 expression and enhances antitumor efficacy of SG. Combinatorial treatment of TROP2 ADCs with epigenetic modulators of TROP2 represent a novel therapeutic strategy for tumors with low TROP2 or SLFN11 expression.
Clinical
|
TROP2 (Trophoblast Cell Surface Antigen 2) • SLFN11 (Schlafen Family Member 11) • CDH1 (Cadherin 1) • ZEB1 (Zinc Finger E-box Binding Homeobox 1)
|
TROP2 expression • SLFN11 expression • TROP2 overexpression • CDH1 expression
|
decitabine • Trodelvy (sacituzumab govitecan-hziy)
over2years
N-glycosylation status of Trop2 impacts its surface density, interaction with claudin-7 and exosomal release. (PubMed, Arch Biochem Biophys)
Furthermore, exosomal release of Trop2 was also decreased in NA and NA mutants. This data suggests that site-specific N-glycan addition determines Trop2 surface density, claudin-7 interaction and exosomal release.
Journal
|
FN1 (Fibronectin 1) • ST14 (ST14 transmembrane serine protease matriptase)
|
TROP2 overexpression
over2years
TROP2 modulates the progression in papillary thyroid carcinoma. (PubMed, J Cancer)
TROP2 promotes the development of PTC. TROP2 expression was correlated with ISG15 and tumor-infiltrating immune cells in thyroid cancer.
Journal
|
TROP2 (Trophoblast Cell Surface Antigen 2) • CEBPA (CCAAT Enhancer Binding Protein Alpha)
|
TROP2 expression • TROP2 overexpression
almost3years
An anti‑TROP2 monoclonal antibody TrMab‑6 exerts antitumor activity in breast cancer mouse xenograft models. (PubMed, Oncol Rep)
Furthermore, in vivo experiments on CHO/TROP2 and MCF7 xenografts revealed that TrMab‑6 significantly reduced tumor growth, whereas it did not show antitumor activities against parental CHO‑K1 and MCF7/TROP2‑knockout xenografts. The findings suggest that TrMab‑6 is a promising treatment option for TROP2‑expressing breast cancers.
Preclinical • Journal
|
TROP2 (Trophoblast Cell Surface Antigen 2)
|
TROP2 expression • TROP2 overexpression
3years
The role and mechanism of human trophoblastic cell surface antigen 2 in the invasion and metastasis of ovarian cancer (PubMed, Zhonghua Zhong Liu Za Zhi)
Trop2 expression is related to ovarian cancer stage and postoperative survival. Trop2 can promote ovarian cancer cell proliferation and metastasis by activating the AKT/β-catenin signaling pathway and knockdown of Trop2 inhibits the progression of ovarian cancer.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • CDH1 (Cadherin 1) • CASP3 (Caspase 3) • VIM (Vimentin) • AKT2 (V-akt murine thymoma viral oncogene homolog 2)
|
TROP2 expression • BCL2 expression • TROP2 overexpression • CDH1 expression • VIM expression
3years
Toxicarioside O Inhibits Cell Proliferation and Epithelial-Mesenchymal Transition by Downregulation of Trop2 in Lung Cancer Cells. (PubMed, Front Oncol)
Overexpression of Trop2 rescues TCO-induced inhibition of cell proliferation and EMT. Our findings demonstrate that TCO markedly inhibits cell proliferation and EMT in lung cancer cells and provides guidance for its drug development.
Journal
|
TROP2 (Trophoblast Cell Surface Antigen 2)
|
TROP2 overexpression
3years
Trophoblast cell surface antigen 2 (TROP2) expression predicts outcome in oral squamous cell carcinomas. (PubMed, Oral Dis)
In summary, our results point to a favorable prognostic significance of TROP2 overexpression in a large cohort of oral cancer patients, suggesting it as an attractive clinical marker.
Journal
|
TROP2 (Trophoblast Cell Surface Antigen 2)
|
TROP2 expression • TROP2 overexpression
3years
Establishment of a novel anti-TROP2 monoclonal antibody TrMab-29 for immunohistochemical analysis. (PubMed, Biochem Biophys Rep)
Western blot analysis showed a 40 kDa band in lysates prepared from both CHO/TROP2-PA and MCF7 cells. Furthermore, TROP2 was strongly detected by immunohistochemical analysis using TrMab-29, indicating that TrMab-29 may be a valuable tool for the detection of TROP2 in cancer.
Journal
|
TROP2 (Trophoblast Cell Surface Antigen 2)
|
TROP2 expression • TROP2 overexpression
over3years
Could trop-2 overexpression indicate tumor aggressiveness among prostatic adenocarcinomas? (PubMed, Ann Diagn Pathol)
TROP2 is overexpressed in various human cancers and TROP2 overexpression appears to correlate with poor prognosis leading to the suggestion that TROP2 could be a therapeutic target for various carcinomas. Our results suggest that TROP2 expression is higher in advanced tumors and these results need to be supported by larger studies.
Journal
|
TROP2 (Trophoblast Cell Surface Antigen 2)
|
TROP2 expression • TROP2 overexpression
over3years
Development and characterization of TrMab‑6, a novel anti‑TROP2 monoclonal antibody for antigen detection in breast cancer. (PubMed, Mol Med Rep)
Furthermore, TROP2 in 57/61 (93.4%) of the breast cancer specimens was strongly detected using immunohistochemical analysis with TrMab‑6. In conclusion, the current study demonstrated that TrMab‑6 may be a valuable tool for the detection of TROP2 in a wide variety of breast cancer types.
Journal
|
TROP2 (Trophoblast Cell Surface Antigen 2)
|
TROP2 expression • TROP2 overexpression
over3years
Trop2: Jack of All Trades, Master of None. (PubMed, Cancers (Basel))
One of these agents, sacituzumab govitecan, has been recently granted an accelerated approval for therapy of metastatic triple-negative breast cancer. In this article, we review the current knowledge about the yet controversial function of Trop2 in homeostasis and pathology.
Review • Journal
|
TROP2 (Trophoblast Cell Surface Antigen 2) • EPCAM (Epithelial cell adhesion molecule)
|
TROP2 expression • TROP2 overexpression
|
Trodelvy (sacituzumab govitecan-hziy)
over3years
Tissue mechanics and expression of TROP2 in oral squamous cell carcinoma with varying differentiation. (PubMed, BMC Cancer)
Overexpression of TROP2 negatively associated with patient survival, degree of tumor differentiation, and tissue mechanics. Taken together, our findings demonstrated that TROP2 may be an indicator of OSCC differentiation leading to the altered mechanical properties of OSCC tissues.
Journal
|
TROP2 (Trophoblast Cell Surface Antigen 2)
|
TROP2 expression • TROP2 overexpression
over3years
Can TROP2 be used as a prognostic marker in endometrioid endometrial carcinoma? (PubMed, Indian J Pathol Microbiol)
Overexpression of TROP2 in endometrioid-type endometrial carcinoma seems to be a poor prognostic factor; it may be useful in determining the biologically more aggressive tumors before the treatment. This early determination is very important to choose the appropriate surgery, adjuvant-treatments, and follow-up.
Journal
|
TROP2 (Trophoblast Cell Surface Antigen 2)
|
TROP2 expression • TROP2 overexpression
almost4years
[VIRTUAL] Clinicopathological features of TROP-2 and pTROP-2 in gastric cancer (AACR-II 2020)
TROP-2 might be associated with metastatic ability of gastric cancer cells, resulting poor prognosis of patients with GC.
Clinical
|
TROP2 (Trophoblast Cell Surface Antigen 2)
|
TROP2 expression • TROP2 overexpression
almost4years
[VIRTUAL] Engineered NK92MICD64 cell docking platform as a combination therapy approach for prostate cancer (AACR-II 2020)
The use of CD64 as a docking platform for therapeutic mAbs was shown to effectively mediate tumor cell killing. Together, these data suggest the potential for our combination cell therapy to be developed as a new therapeutic approach for PCa.
Late-breaking abstract • Combination therapy
|
TROP2 (Trophoblast Cell Surface Antigen 2) • FCGR3A (Fc Fragment Of IgG Receptor IIIa)
|
TROP2 overexpression